Knicks conference finals appearance drives MSG Ticket prices skyward
This story originally appeared on Due
New York City has erupted in basketball fever as the Knicks reach the National Basketball Association's conference finals for the first time in a quarter-century, causing ticket prices at Madison Square Garden to reach unprecedented heights.
The team's long-awaited return to this advanced playoff stage has ignited a purchasing frenzy among fans desperate to witness history in person. This marks a significant moment for a franchise that has experienced multiple rebuilding phases and disappointments since its last conference finals appearance in 1999.
Historic Return Fuels Market Surge
After 25 years of waiting, Knicks fans are opening their wallets to secure seats for the upcoming games. The demand reflects both the team's passionate fan base and the significance of this playoff run in the context of the franchise's recent history.
Madison Square Garden, often referred to as 'The World's Most Famous Arena,' is seeing ticket prices that match its prestigious reputation. The venue, which has hosted countless memorable NBA moments throughout its history, is once again the center of basketball attention in New York.
Economic Impact of Playoff Success
The surge in ticket prices represents more than just basketball enthusiasm—it demonstrates the economic power of successful sports franchises in major markets. Local businesses around Madison Square Garden are also experiencing increased activity as fans gather before and after games.
The financial windfall extends beyond just primary ticket sales. The secondary market has exploded with resellers listing tickets at multiples of face value, creating both opportunities and challenges for fans hoping to attend the games.
Some notable effects of the Knicks' playoff run include:
Increased merchandise sales throughout the city
Higher reservation rates at restaurants near Madison Square Garden
Greater television viewership for Knicks games
Fan Reaction and Cultural Significance
The willingness of fans to pay premium prices highlights the cultural significance of the Knicks in New York City. Despite years of mediocre performance, the team has maintained a loyal following that has eagerly awaited this return to prominence.
Social media platforms have been flooded with fans sharing their excitement, ticket purchase stories, and even complaints about the high prices. This online activity further fuels interest in the games and contributes to the escalating ticket market.
The Garden' has always been a special place for basketball, but these conference finals games represent a new peak in both fan enthusiasm and financial investment required to attend.
Basketball analysts note that the Knicks' return to the conference finals represents more than just a sporting achievement—it's a cultural moment for a city that prides itself on basketball tradition. The team's success has united diverse segments of New York's population in a shared experience.
As the series approaches, the question remains whether ticket prices will continue to climb or if they'll reach a ceiling based on what even the most dedicated fans are willing to pay. Either way, Madison Square Garden will be the hottest venue in New York City as the Knicks continue their quest for an NBA championship.
The post Knicks conference finals appearance drives MSG Ticket prices skyward appeared first on Due.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Factbox-Healthcare firms see growing activist investor involvement in the past year
(Reuters) -Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. NOVO NORDISK Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN In January, private equity firm KKR built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Prep talk: Mira Costa's special teams trio ready to deliver
Maybe it's knowing the beach is a short walk from their high school campus, but the special teams trio of punter Jackson Shevin, long snapper Jackson Reach and kicker Nico Talbott are feeling relaxed, comfortable and confident for Mira Costa High's football team. Early in the season, fans sometimes need to close their eyes and pray when there's a punt or PAT attempt. The special teams play can be that bad. At Mira Costa, this coming season should be a good one for the special teams. The two Jacksons, Shevin and Reach, did their roles last season. Shevin is also a holder on field goals. Talbott assumes the No. 1 role for kicking. And Reach rarely leaves the field, because he's also the team's standout linebacker. On any football team, it's always intriguing to see how the special teams players blend in. Many are soccer players trying to learn the football culture. The Mira Costa trio work well together, and it helps with their versatility. Mira Costa opens its season Aug. 29 against St. Francis. … This is a daily look at the positive happenings in high school sports. To submit any news, please email Sign up for the L.A. Times SoCal high school sports newsletter to get scores, stories and a behind-the-scenes look at what makes prep sports so popular. This story originally appeared in Los Angeles Times.
